Reprogramming cell death: BCL2 family inhibition in hematological malignancies.
about
Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive reviewTargeting autophagy to sensitive glioma to temozolomide treatmentThe potential of venetoclax (ABT-199) in chronic lymphocytic leukemiaThe insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potentialThe modified Yi qi decoction protects cardiac ischemia-reperfusion induced injury in rats.Silence of MCL-1 upstream signaling by shRNA abrogates multiple myeloma growth.Bilberry extract (Antho 50) selectively induces redox-sensitive caspase 3-related apoptosis in chronic lymphocytic leukemia cells by targeting the Bcl-2/Bad pathway.Rare double-hit with two translocations involving IGH both, with BCL2 and BCL3, in a monoclonal B-cell lymphoma/leukemiaClinical significance of bax/bcl-2 ratio in chronic lymphocytic leukemia.Preclinical modeling of novel therapeutics in chronic lymphocytic leukemia: the tools of the tradeThe pyrrolo-1,5-benzoxazepine, PBOX-15, enhances TRAIL‑induced apoptosis by upregulation of DR5 and downregulation of core cell survival proteins in acute lymphoblastic leukaemia cells.Nanoparticle-based strategy for personalized B-cell lymphoma therapy.PNT2258, a novel deoxyribonucleic acid inhibitor, induces cell cycle arrest and apoptosis via a distinct mechanism of action: a new class of drug for non-Hodgkin's lymphoma.Upregulation of Bcl-2 and Its Promoter Signals in CD4+ T Cells during Neuromyelitis Optica Remission.FAS/FASL gene polymorphisms in Turkish patients with chronic myeloproliferative disordersPotential role of BCL2 in the recurrence of uterine smooth muscle tumors of uncertain malignant potential.Protective effects of tanshinone IIA sodium sulfonate on ischemia-reperfusion-induced myocardial injury in ratsActivating somatic mutations in diffuse large B-cell lymphomas: lessons from next generation sequencing and key elements in the precision medicine era.Emerging understanding of Bcl-2 biology: Implications for neoplastic progression and treatment.New dimension in therapeutic targeting of BCL-2 family proteins.Pharmacodynamic considerations of small molecule targeted therapy for treating B-cell malignancies in the elderly.Pro-survival signal inhibition by CDK inhibitor dinaciclib in Chronic Lymphocytic Leukaemia.Comparison of in vitro antileukemic activity of obatoclax and ABT-737.The SF3B1 inhibitor spliceostatin A (SSA) elicits apoptosis in chronic lymphocytic leukaemia cells through downregulation of Mcl-1.RPPA-based protein profiling reveals eIF4G overexpression and 4E-BP1 serine 65 phosphorylation as molecular events that correspond with a pro-survival phenotype in chronic lymphocytic leukemia.Regulation of growth of human bladder cancer by miR-192.Imaging cellular distribution of Bcl inhibitors using small molecule drug conjugates.Pevonedistat, a Nedd8-activating enzyme inhibitor, sensitizes neoplastic B-cells to death receptor-mediated apoptosis.The IGF-1 receptor inhibitor picropodophyllin potentiates the anti-myeloma activity of a BH3-mimeticQuantitative proteomics to characterize specific histone H2A proteolysis in chronic lymphocytic leukemia and the myeloid THP-1 cell line.Genetic Predisposition to Chronic Lymphocytic Leukemia Is Mediated by a BMF Super-Enhancer Polymorphism.B-cell receptor-guided delivery of peptide-siRNA complex for B-cell lymphoma therapy.XIAP over-expression is an independent poor prognostic marker in Middle Eastern breast cancer and can be targeted to induce efficient apoptosisBH3 Mimetics for the Treatment of Prostate Cancer.Effects of Electrochemotherapy with Cisplatin and Peritumoral IL-12 Gene Electrotransfer on Canine Mast Cell Tumors: a Histopathologic and Immunohistochemical Study.Bcl-2 delays cell cycle through mitochondrial ATP and ROS.Moving Beyond Maximum Tolerated Dose for Targeted Oncology Drugs: Use of Clinical Utility Index to Optimize Venetoclax Dosage in Multiple Myeloma Patients.MicroRNA profile in HBV-induced infection and hepatocellular carcinoma.Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update.Synergistic cytotoxicity of a prostate cancer-specific immunotoxin in combination with the BH3 mimetic ABT-737.
P2860
Q27304386-3BE701F8-0DB0-4267-8112-871B968A372CQ28066270-572B3A09-BEA8-4258-BFDA-D4D8DFD4CE4AQ28075504-5BBA26A2-6412-409E-A9F1-378A5AF22697Q28075927-E7F931BF-F278-4E8E-8561-5D031C5E8567Q33823814-B65E2364-4530-40D0-B8B9-3EB679202A2CQ34566043-F3E4C59B-7E05-41AB-AC88-F9C36B5C331DQ35165791-E977AC19-0CB1-43AC-BE38-BE56A0FE4FDBQ36417128-5BBA7A1C-3B99-4841-AB34-346CCA4CFCF0Q36420752-CF721CCE-BD39-4BC9-859B-190CBAF6048FQ36867755-94CD6268-9F99-49E9-B4AD-338B4156835EQ36992184-B50192F7-8BA7-45F5-BF5E-8CAAE737DEE6Q37426956-117D1206-7EAC-40E9-A8DA-8849A45EDADDQ37520553-A34380A1-9BFB-494C-8894-01883A0B770BQ37601388-4984B00D-2A23-41AA-9280-FCBDEB6364C4Q37675522-D8410AFC-4575-46B5-9BC6-180E82075BA2Q37707683-40986E99-C51E-443F-B61C-8054C4CEE143Q37736291-2CF5F75C-ABD7-4230-A016-0AF726E32A07Q38240579-B0D6A386-60F4-46E0-8D14-A59BB994D017Q38398064-4B9D229D-3A1E-4D81-875E-AA2609CB495EQ38477617-FB22352D-7A4F-4926-8E3A-0013459ABC6DQ38544216-A4051339-6E66-4CD3-8C5C-0784A6BAB993Q38755091-C2733C8A-8F57-40D6-B4E7-F7537285634FQ38793940-059FA3EA-AC25-498B-B9DE-BA0675FC174EQ38826234-D09919C5-FE64-4E89-9721-9A435EB9AE19Q38872127-FD3F5C4D-FCE5-43F9-ABC3-B3BF19934452Q38922382-B2CE978D-BE69-4D99-84FB-9ACFDF0A8BB3Q38946207-737C9EB2-6C4A-4922-81C6-55B95051276CQ38972048-AC2FA33D-4CF1-43E1-A435-651DAF542B83Q38976876-4F76128D-3268-43F5-A0D6-27B72184FDA8Q38990718-1E39015E-7F91-4120-9A17-1DF372A5D46FQ40622219-967E3119-576F-4F00-8B24-D9212F07DF97Q40706746-9ABD2470-F904-432C-ADB3-41A66DC7C07EQ41279921-2BD8C08F-BDFA-40C2-94D7-FA7C3DC3B81EQ41463153-21F1B664-4C27-4DCA-9ECA-AF587B181750Q41678090-59430E6A-4114-4C7C-9CD5-30121BF41656Q42802217-529C6C0E-A1F9-451C-9014-2895BFD55081Q45057327-0170ACF3-7354-4781-8E33-DBD14CF227F4Q47155849-1C6FE5E5-4E98-428F-B73C-31BF55A51950Q47348957-C41D0E08-2099-408A-80A9-00D5F2F5A417Q47349096-145DE8DD-F347-4162-9732-7AB7F9EC74BE
P2860
Reprogramming cell death: BCL2 family inhibition in hematological malignancies.
description
2013 nî lūn-bûn
@nan
2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Reprogramming cell death: BCL2 family inhibition in hematological malignancies.
@ast
Reprogramming cell death: BCL2 family inhibition in hematological malignancies.
@en
type
label
Reprogramming cell death: BCL2 family inhibition in hematological malignancies.
@ast
Reprogramming cell death: BCL2 family inhibition in hematological malignancies.
@en
prefLabel
Reprogramming cell death: BCL2 family inhibition in hematological malignancies.
@ast
Reprogramming cell death: BCL2 family inhibition in hematological malignancies.
@en
P1433
P1476
Reprogramming cell death: BCL2 family inhibition in hematological malignancies.
@en
P2093
Lydia Scarfò
P356
10.1016/J.IMLET.2013.09.015
P50
P577
2013-09-01T00:00:00Z